Protective effect of recombinant human interleukin-2 against lethal infection caused by Klebsiella pneumoniae.
The effects of recombinant human interleukin-2 (rIL-2) administered prophylactically on the death of CBA/J mice challenged with Klebsiella pneumoniae 27 intraperitoneally were examined. rIL-2 administered subcutaneously at 20 micrograms per mouse for 7 days enhanced survival after a lethal challenge. The injection of anti-asialo GM1 antibody did not influence the effect of rIL-2. In mice given rIL-2, the number of peritoneal macrophages increased, and the infiltration of polymorphonuclear leukocytes (PMN) into the peritoneal cavity after the bacterial challenge was enhanced. In addition, adoptive transfer of sera and peritoneal exudate cells (PEC), consisting of an approximately equal number of macrophages and PMN, obtained from mice given rIL-2 enhanced resistance to a K. pneumoniae infection, compared with adoptive transfer of sera and PEC obtained from mice not given rIL-2. These results indicate that rIL-2 protects mice from a lethal challenge with K. pneumoniae, and suggest that the protective effect is due to an increase in the number of phagocytic cells and in the cooperative activity of the sera and the phagocytic cells.
Iizawa
Y
Y
Research and Development Division, Takeda Chemical Industries, Ltd., Osaka.
Nakao
M
M
Kondo
M
M
Yamazaki
T
T
D000818:Animals; D000907:Antibodies, Bacterial / Q000276:immunology; D015169:Colony Count, Microbial; D005260:Female; D005677:G(M1) Ganglioside; D006028:Glycosphingolipids / Q000276:immunology; D006801:Humans; D007376:Interleukin-2 / Q000627:therapeutic use*; D007710:Klebsiella Infections / Q000209:etiology / Q000401:mortality / Q000517:prevention & control*; D007711:Klebsiella pneumoniae / Q000187:drug effects / Q000276:immunology; D051379:Mice; D008808:Mice, Inbred CBA; D009504:Neutrophils / Q000187:drug effects / Q000276:immunology; D010529:Peritoneal Cavity / Q000382:microbiology; D010587:Phagocytosis / Q000187:drug effects; D011994:Recombinant Proteins / Q000627:therapeutic use; D015996:Survival Rate
D000907:Antibodies, Bacterial; D006028:Glycosphingolipids; D007376:Interleukin-2; D011994:Recombinant Proteins; D005677:G(M1) Ganglioside; C018835:asialo GM1 ganglioside